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Ethical Issues in
AIDS Research
Michael A. Grodin, M.D.
Paula V. Kaminow, J.D.
Raphael Sassower, Ph.D.
There is a needfor carefully controlled and scientifically rigorous research studies ofthe
acquired immunodeficiency syndrome (AIDS). The morbidity and mortality associated
with AIDSpatients and the public health concernsfor control ofthis epidemic have dis-
torted the usualprocess ofresearch. The Institutional Review Board at Boston City Hospi-
tal is suggested as an appropriate mechanismfor clarifying the distinctions between
research and innovative therapies andfor assuring the protection ofthis vulnerable popu-
lation ofresearch subjects. This article addresses ethical concerns relating to the time
frame ofresearch, drug and antibody testing, vaccine trials, and questions ofjustice in
micro- or macro-allocation. The unique problems in AIDS research with informed consent
and confidentiality are discussed. Finally, the need is outlinedfor careful balancing of
individual welfare and rights and those ofsociety.
Perhaps the least controversial point in all discussions about AIDS and AIDS-related
complex (ARC) is the need for research. The need to discover the etiology, natural
history, epidemiology, and treatment of AIDS is indisputable. However, ethical dilemmas
surrounding the priorities, methodologies, and timing of research strategies pose unique
problems for patients, researchers, clinicians, hospitals, institutional review boards
(IRBs), public health workers, health care policymakers, and society at large. 1
From the earliest case reports in late 1979 of male homosexuals with Kaposi's sarcoma,
immunosuppression, and opportunistic infections, through May 1984, when the human
immunodeficiency virus (HIV, formerly known as HTLV-EQ/LAV) was accepted as the
etiologic agent of AIDS, to the present, medical scientists have been and continue to be
involved in clinical, epidemiological, and basic science research into AIDS. 2 The Centers
for Disease Control (CDC) has been involved in surveillance and epidemiological re-
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search, while other federal agencies, such as the National Institutes of Health and the
National Cancer Institute, have sponsored and carried out other investigations. Privately
funded commercial, pharmaceutical, and hospital-based research has also been initiated.
The rapid mobilization of the medical research community in the face of this deadly, im-
mensely complex, and emotionally charged public health problem has caused some wob-
bles in the balance that is carefully maintained between individual patient welfare and the
public welfare— a balance that has always been an integral part of the ethical principles of
medical research.
The Nature ofAIDS Research
The primary goal of medical research is to contribute to the development of general
knowledge about a particular disease or condition; the primary goal of clinical therapy, on
the other hand, is to benefit the individual patient. When medical research enters the
clinical therapy setting in the form of testing new drugs, vaccines, or diagnostic proce-
dures, a blurring between these two objectives often occurs. The goal of participating in
the testing of a new drug or an innovative therapy may be one thing for the patient and the
clinician team, another for the research scientist, and quite another for the sponsoring
agency.
The potentially competing interests of the various parties involved in human experimen-
tation present a crucial issue in AIDS research. Additional surveillance is needed because
of the wide array of unvalidated and innovative therapies being tested on AIDS patients —
members of a special population with a fatal disease who may be willing to incur greater
risk to themselves for the good of others. This surveillance must be undertaken by a group
that represents the interests not only of the researchers and sponsoring agencies but also
of the patients and the public at large.
Institutional Review Boards
IRBs are the intra-institutional committees established under regulations promulgated by
the U.S. Department of Health and Human Services. 3 They are mandated to review re-
search involving humans and to monitor the protection of human subjects in order to en-
sure that socially accepted ethical norms are met. 4 IRBs require that research protocols
involve sound scientific design; competent methods of investigation; favorable balance of
risks and benefits; adequate informed-consent mechanisms; equitable selection of sub-
jects; justification for research on special populations; and consideration of compensation
for research-induced injury. Those who comprise IRBs fall into one of two groups,
broadly speaking: individuals who are affiliated with the institution or hospital, such as
physicians, nurses, scientists, pharmacists, and public health workers; and unaffiliated
lay members, such as philosophers, theologians, lawyers, and other community repre-
sentatives. Such broad representation and mandated authority place IRBs in the pivotal
position necessary to provide additional surveillance ofAIDS research.
Time Framefor Research
The high morbidity and mortality of AIDS patients and the serious public health concerns
regarding the etiology, natural history, and transmission of HIV have accelerated the
standard medical research time frame for AIDS research. Although the pressure to speed
up AIDS research is understandable, perhaps even desirable, such distortion of standard
research practice implies potential dangers. Moreover, the publicity concerning AIDS re-
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search has created a public image of medical research that is quite different from reality.
Standard medical research is a slow, meticulous process. Once the safety and efficacy
of proposed therapies have been established, controlled clinical tests are performed. To
minimize human risk, animal studies are used when possible before human studies; com-
petent adult patients are studied before incompetent patients; and, when applicable,
healthy volunteers are studied before sick or exposed volunteers. Special protections are
needed for the study of populations who are at special risk of possible coercion or duress.
As a rule, indiscriminate or premature use of therapies that have not been vigorously
tested and verified is discouraged.
In AIDS research, however, there has been a rapid movement from basic-science stud-
ies to clinical trials. Researchers have been quick to report the results of their work, and
the publication of these results has been almost immediate through the news media. Data
from such research may be quickly transferred to the clinical setting, where they are often
applied without controlled clinical testing. This is understandable. Physicians want to be
able to treat their AIDS patients as effectively as possible, and they also want to be able to
educate their patients and the public appropriately in order to prevent the spread of AIDS.
AIDS patients, searching for hope of survival, scan the medical literature and news re-
ports for access to new drugs or therapies. Premature media coverage of research results
has often been accompanied by unwarranted claims of success, thereby raising the pub-
lic's expectations unfairly. When the initial studies of interferon and interleukins were
released by the press, AIDS patients from all over the country flooded researchers with
requests for treatment.
Public health concerns about the prevention and spread ofAIDS have caused the early
introduction of research data into public policy debates. Epidemiological studies are
sought as a means of dealing with disease risk management. Such data are used in argu-
ments for and against policies regarding persons with AIDS and their school attendance;
the safety and appropriateness of their employment; acceptance for health and life insur-
ance; and possible large-scale screening and quarantine.
Through the rapid publication of their data, many investigators have gained professional
and personal renown as well as guarantees of future research funding. The race to cure
AIDS has even spurred one research team in France to bring a legal suit against a U.S.-
based research team in an argument over who really discovered the AIDS virus. 5
The rather unorthodox methodology ofAIDS research has led to several problems.
Data are presented which have not been adequately tested or controlled. Reports of con-
flicts in data or errors in data cause alarm among clinicians and patients alike. Premature
claims of certainty about results which prove to be inaccurate and the continual updating
and reclarifying of results of epidemiological studies and clinical tests have confused the
public and shaken its confidence in AIDS research.
Because of the urgency ofAIDS research, IRBs have felt increased pressure from both
researchers and the public to approve AIDS research protocols rapidly. Since it is both the
function and responsibility of IRBs to protect human subjects in medical research, they
must assume the crucial tasks of helping to maintain ethical and standard research proce-
dures and of helping to develop responsible modifications in those procedures. However,
IRBs cannot and should not be the sole gatekeepers safeguarding the integrity of AIDS
research.
AIDS Drug Testing
The discovery of experimental antibiotics and antiviral agents that may help fight AIDS
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and the complicating opportunistic infections found in AIDS patients has spurred the
early clinical testing of such drugs. Research protocols involving these drugs represent
some of the most ethically complex situations that come before IRBs. Researchers ask
IRBs for approval to bypass standard research procedures and to grant compassionate use
of drugs they believe will be of particular benefit to AIDS patients. Private pharmaceuti-
cal companies are eager to introduce their new antiviral products, because sometimes the
mere suggestion of the possible success of an experimental antiviral agent has caused
stock in the companies producing such drugs to rise rapidly. Requests are also made for
special, expedited approval for new uses of approved drugs without controlled trials or
standardized testing.
An excellent example of the dilemmas associated with drug testing in AIDS patients is
the case of Azidothymidine (AZT). 6 From the moment this antiviral agent was shown to
have some efficacy with the AIDS virus, an emotionally charged and ethically complex
series of questions arose. Should the drug go through the standard three-phase, slow med-
ical research protocol of exhaustive testing of safety and efficacy in animals and humans?
What patients should be used in human experimentation, and how should they be se-
lected? Should a standard controlled clinical trial of the experimental agent matched
against a placebo-control group be undertaken to prove clinical efficacy scientifically?
How much of a role should AIDS patients, ARC patients, physicians, scientists, drug
companies, and the public play in determining the research trials ofAZT? If a ran-
domized clinical trial of placebo versus AZT were undertaken, at what point should the
code be broken, identifying which patients received AZT and which received placebo in
such a blind study? Once a trend toward efficacy has been established in the course of
clinical experimentation, when should the trials be terminated and the drug made availa-
ble? Is a desperately ill, dying patient with AIDS the appropriate subject for study, or are
patients with ARC or HIY-antibody-positive patients with no symptoms a more justifiable
group in which to conduct clinical trials? How should one assess the relative risks and
benefits in these populations? Should dying patients be included in the randomization, or
should they be treated with drugs outside of clinical trials as a last glimmer of hope? Can
patients who are dying give an informed consent? Even if they are competent to do so,
should they be approached with new, untested drugs with no clear evidence of safety or
efficacy? Who should bear the cost of the research project and of the drugs themselves? If
a drug appears to be effective late in a clinical trial, can the research subject be asked to
pay for the drug? After the research trials are over, can a patient who appears to have
responded continue to have access to the experimental agent? As newer drugs become
available, should they be tested against placebo controls or against other existing drugs,
such as AZT? What control should IRBs have in the resolution of these dilemmas? And,
finally, what role should such regulatory bodies as the Department of Health and Human
Services or the Food and Drug Administration (FDA) play in monitoring and granting
final approval for AIDS drugs?
The history of AZT, from its early synthesis as an anticancer drug through animal and
human testing and then to FDA approval and marketing, represents a fair balance between
the expediency of drug development and the protection of human subjects at risk. AZT
was first tested for in vitro activity against HIV. When the drug's efficacy with HIV had
been demonstrated, animal trials were undertaken. The first human experiments were
conducted at the National Cancer Institute as an open, nonrandomized trial. Once AZT
showed promise as an agent in vivo against HIV, a randomized, placebo-controlled clini-
cal trial was carried out at several medical institutions caring for AIDS patients. Early in
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the controlled trials, researchers broke the code to identify patients receiving the drug
when it became apparent that some patients benefited from the trial more than others.
On the basis of accumulated data from these trials, the FDA approved AZT for clinical
use on March 19, 1987. After AZT was approved, the manufacturer began to charge for
its use. Initially the cost ofAZT was approximately $10,000 per year, but the increasing
market and efficiency of production have already led the manufacturer to begin lowering
this figure. However, the cost may still present an economic hardship for some. Increased
production of the drug seems to have alleviated the problems of access that accompanied
its emergence. Insurance coverage may vary, though it appears that access has not been
limited nationally by inability to pay. In Massachusetts, all third-party payers, including
Medicaid, have covered the cost of AZT. Massachusetts has also recently established a
program to cover the cost of the drug for patients who have no other means to pay. AZT
has thus proven to be a paradigm for a reasonable approach to drug testing in AIDS.
In June 1987, partly in response to AIDS drug testing, the FDA issued final regulations
outlining procedures under which "promising, investigational new drugs could be made
available to desperately ill patients before general marketing begins." 7 The regulation
applies to "patients with serious and immediately life-threatening diagnoses for which no
comparable or satisfactory alternative drug or other therapies exist." The FDA also de-
fined "conditions under which drug manufacturers may charge for investigational new
drug products." It remains to be seen whether such FDA regulatory changes will accom-
plish the goal of releasing new drugs to patients prior to marketing while at the same time
protecting the scientific clinical-trials process for testing safety and efficacy and protect-
ing the human subjects participating in research.
HIVAntibody Testing
Perhaps the clearest example of the quick transition ofAIDS research from the laboratory
to the clinic is the HIV antibody test. Because of the need to identify subjects carrying the
HIV antibody in order to protect the blood supply from contaminated donor units, anti-
body testing was one of the first priorities of AIDS research. The test was also necessary
for quantifying epidemiological data and for therapeutic trials and screens. Once devel-
oped, the HIV antibody test was rapidly introduced into research protocols and clinical
practice, but problems of sensitivity and specificity resulted because experience with the
significance and variances of the test was not complete. Beyond test reproducibility, ques-
tions about the reliability of HIV antibody positivity and the significant false-positive and
false-negative rates caused concern about how quickly this test was being used for clinical
screening and public policy guidelines. Extending the use of the HIV antibody test to
patient care is complicated by the questions of where, when, how, and why it should be
used. In using antibody testing, the distinctions between purposes of epidemiology, diag-
nosis, and public policy have not always been clear.
HIV Vaccine
As more is learned about the structure and function of the AIDS virus, several research
groups have begun work on the development of an HIV vaccine. If and when such a vac-
cine becomes available, how should it be tested? Do safety and efficacy studies in animals
warrant the move to human studies? Who should be used for human studies — patients
who are already infected with the virus, or normal subjects with no evidence of viral
infection? Is it appropriate to test the vaccine on at-risk populations when education and
change in lifestyle are known to be effective preventive measures? Once the vaccine is
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administered, how will immunity be tested? Should such subjects be challenged with the
virus or allowed or even encouraged to continue their high-risk behavior? The laboratory
development of an HIV vaccine may raise the hope of universal protection through immu-
nization, but there will be significant ethical debate about research trials and subsequent
recommendations for widespread clinical use.
Justice in Micro-Allocation
The main concern of persons with AIDS is the possible avoidance of what appears to be an
inevitable early death. This fact brings into focus the problem of population selection for
AIDS research. It is reasonable to assume that some experimental drugs will eventually
be effective in combating AIDS. Are chances of survival increased when an AIDS patient
participates in many research protocols involving different experimental drugs? How are
participants to be selected? Who serves as the control group for these drug trials? Should
selection be based on the ability to pay, on special needs, or on special merit? Since par-
ticipation in AIDS research may be viewed as a public good that may also be helpful to the
individual AIDS patient, questions about distributive justice must be addressed. How
should promising experimental therapies be distributed among all too many claimants in a
research setting?
Distributive justice also enters into the problem of disseminating knowledge about
AIDS research. Who should know about it? How should such knowledge be provided?
Who should pay for it? Should the public as a whole bear the burden of learning and
teaching all there is to know about AIDS? Should all the media outlets devote time to
AIDS-related issues? Should all public schools devote regular sessions to AIDS-related
issues? Should the public be alerted as soon as possible to all new stages of AIDS re-
search?
Justice in Macro-Allocation
Most medical research in the United States is funded either by government agencies or by
private foundations and corporations. More specifically, when the research pertains to
national epidemics or to medical ailments that are of concern to a wide portion of the
population, funding has been provided largely by government agencies. Because AIDS
was not viewed at first as an epidemic of national concern, however, AIDS research was
initially given little attention and little funding.
Several explanations can be given for this early public policy decision. First, AIDS was
thought to afflict only a small minority and thus was not a national concern. Second,
some viewed AIDS in theological terms and claimed that this disease was divine punish-
ment against the immoral acts of homosexuals. Third, political pressure to do anything
about AIDS was lacking. This is understandable, given the politically conservative stance
of the current administration, especially toward the population at risk for developing
AIDS.
Political compromises regarding AIDS became quite evident to the growing population
of potential AIDS patients. The male homosexual populations of cities like Boston, New
York, and San Francisco flexed their political muscles and demanded that their city gov-
ernments do something about AIDS. These powerful grassroots efforts provided the pop-
ular support that city mayors needed to pressure their state legislators for funds to help
with AIDS research and education programs. Finally, through pressure from local and
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state governments and the public at large, the federal administration began to provide
funds for AIDS research through the office of the secretary of health and human services.
If only a marginal segment of the population is afflicted with a certain disease, it seems
reasonable and just that only a small proportion of public funds earmarked for medical
research be allocated for the study of that disease. This was the original proposition advo-
cated in the case ofAIDS on both logical and ethical grounds. But this reasoning cannot
hold. Now that cases of heterosexual partners and children with AIDS have been con-
firmed, it remains unclear how small or large the at-risk population is. Because the poten-
tial risk to the public at large is uncertain, it is not obvious how to proceed. Should funds
be provided only according to the proven proportion of the population which has already
contracted the disease? Or should the potential spread ofAIDS be taken into account?
Questions also arise concerning the priority of other ongoing medical research. Should
federal funding for the less urgent areas of medical research be halted and those funds
channeled to AIDS research? Such a suggestion could be defended if one were able to
show that unless the government did just that, millions of lives would be endangered.
Arguments of this sort presuppose that it is possible to establish a medical research
agenda with an agreed-upon set of priorities determined by society as a whole. There are,
of course, practical problems with setting such an agenda. How could all of society partic-
ipate in such a discussion? Can any procedure guarantee democratic control of the setting
of these priorities?
A discussion of the macro-allocation of resources for AIDS research would not be com-
plete without considering what it is that private foundations and corporations have at stake
in funding AIDS research. Are these organizations concerned with the well-being of those
afflicted with AIDS? Or are they hoping to discover the cure in order to capitalize on their
discovery and make huge profits? It is possible to claim that the motives for research are
unimportant as long as the results are beneficial to patients and society. Moreover,
whether or not profits will be secured remains an open question that has little bearing on
the ability of the private sector to supplement the federal funds allocated for AIDS re-
search. There are always potential conflicts of interest on the part of those involved in
research, in terms of compromises that might be made to maximize profits.
Although IRBs should be cognizant of these issues, their concern about funding sources
is limited to the ways in which financing may affect the well-being of human subjects. Is
there adequate funding to assure the completion of the proposed research, so that the
claimed benefits will indeed outweigh the risks the subjects are asked to incur? It should
also be noted that the role of the IRBs is not to set up or implement any specified research
agenda but merely to ensure the protection of the subjects who are enrolled in medical
research projects.
It is impossible and would be presumptuous to provide any answers or even rules for
action regarding the many questions raised so far. The main purpose of this discussion
and that which follows is to illustrate the complexity of the ethical issues surrounding
AIDS, both for society as a whole and for the individuals involved, and to show that these
issues are intimately connected to other social and political concerns.
Informed Consent
Obtaining informed consent in any type of research is a demonstration of respect for an
individual's autonomy. Informed consent has three primary components:
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• the individual giving consent is mentally competent;
• the individual giving consent is presented with enough information to make
rational decisions; and
• the consent is uncoerced— freely given by a nonvulnerable, autonomous
individual.
AIDS research raises ethical questions about each of these components. First, when
research involves a new vaccine or treatment, both the scientific community and the sub-
jects are faced with more unknowns than knowns. Because AIDS research is so new, the
range and magnitude of the unknowns are great. Researchers may believe that their ethical
obligations are fulfilled by advising the subjects of the range of unknowns and asking
them to weigh the potential risk/benefit ratio on that basis. However, at some point, par-
ticularly where new ideas are being rushed through the research system and virtually no
information may be available, potential subjects may be placed at too great a risk. IRBs
need to make this kind of assessment and, if necessary, restrict participation in such a
study.
Second, some persons with AIDS show clinical signs of a central nervous system dys-
function associated with the AIDS virus. To the extent that such symptoms render them
mentally incompetent, they will be unable to give informed consent. A question that arises
when research is directed at central nervous system AIDS is, Who, if anyone, can or
should give consent for the patient? This question arises in both clinical and research
settings. Generally, substitute decision makers (for example, parent, spouse) are ap-
proached. 8 But what happens when an individual with AIDS is alienated from his or her
family and has no legally recognized spouse? The individual who is closest to and who
best knows the patient may not be legally recognized as such and may know of difficulties
between the patient and other family members.
Third, and finally, when research involves a dying patient whose body has been ravaged
by a continuous series of recurring infections and the patient is given a glimmer of relief,
the consent can hardly be considered freely given by a nonvulnerable person. Or, how
about the symptomatic or asymptomatic individual who feels a sense of guilt from the
possibility of having infected a loved one and who is willing to undergo unusual risks to
make amends? How about the intravenous (IV) drug user who may link the research with
access to methadone?
What obligations do researchers have to look beyond the surface of consent and protect
the individual? How paternalistic may the researcher be? Or, conversely, are members of
a group uniquely infected by a virus under some obligation to society and the other mem-
bers of their group to sacrifice their individuality in order to help avert further infection?
IRBs are in a position to protect the rights of individuals to make autonomous and in-
formed decisions and not be pressured either by researchers or by the population of per-
sons with AIDS. In this sense, then, IRBs may be considered paternalistic when attempt-
ing to maintain the rights and welfare of potential research subjects.
Confidentiality
Preservation of the confidentiality of individuals with AIDS or of other participants in
AIDS research is a major concern of clinicians, researchers, lawyers, ethicists, and com-
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munity groups. 9 The right to privacy, as associated with individual liberty and autonomy,
is an important ideal in our society. All medical clinicians and researchers are obligated to
maintain confidential information acquired in the clinical and research settings. In the
therapeutic environment, such ethical obligations are supported by legal rights in order to
permit a free exchange of information between patient and clinician so that possible bene-
fits of treatment will be maximized. The federal guidelines for federally funded research
require that researchers provide for confidentiality of records and subject information and
that IRBs consider this issue when reviewing research protocols. 10
The complexity of AIDS research makes difficult demands on researchers with regard
to confidentiality. First, in a society in which homophobia exists and AIDS phobia runs
rampant, the risk of information leaks is quite high. Individuals may be stigmatized gen-
erally for being gay or drug users, or specifically for having a fatal, contagious disease.
There are cases in which people either with AIDS, ARC, or HIV antibody positivity have
been denied insurance benefits or have suffered the loss of their jobs. Medical providers,
acting on their unsubstantiated fears of treating individuals with AIDS, may inappropri-
ately gown or glove before entering the patient's room, may over-isolate AIDS patients,
or may even refuse to treat AIDS patients altogether. Another repercussion of AIDS is a
family's discovery that a family member is a homosexual or an IV drug user. Further,
certain activities that contribute to the spread of AIDS, such as prostitution and IV drug
use, are illegal. Knowledge of the individual's status may be followed by legal prosecu-
tion. However, in a fear-driven society, failure to release information about particular
individuals with AIDS may subject all members of high-risk groups to being ostracized,
denied benefits, and treated in a discriminatory fashion. Should such a societal response
justify invasion of an individual's privacy and liberty?
Recognizing the importance of medical research, both the federal government and the
Massachusetts legislature provide mechanisms for protecting confidentiality by limiting
access to research records in certain cases. Under federal law, a researcher can apply for
a confidentiality certificate when engaged in mental health research, including research
on the use and effect of alcohol and psychoactive drugs, to prohibit access to information
by compulsory process. 11 The Massachusetts statute similarly protects certain information
from release under subpoena. 12 Laws regarding the protection of confidentiality and ac-
cess to research records may vary among states.
One major dilemma for researchers who learn that an individual has AIDS, ARC, or
HIV antibody positivity and may therefore be infectious is how to preserve the patient's
confidentiality while at the same time protecting medical personnel from exposure to
AIDS. An example from Boston City Hospital will illustrate this point. When the HIV
antibody test was first developed, it was available only for research and blood bank use,
not for clinical purposes. At that time, the Centers for Disease Control and the Massachu-
setts state health agencies felt that, in the absence of treatment for the AIDS antibody, the
information would be of little clinical value and would result only in negative conse-
quences for the patient. Since that time, the CDC has become more interested in tracing
the course of the virus at earlier stages and has encouraged antibody testing in clinical
settings where the information would assist clinical management.
Seroepidemiological studies of HIV with IV drug users, including a substantial number
of pregnant addicts, were conducted at a drug treatment clinic operated by Boston City
Hospital. The researchers in this instance had information about the clients which they
could not disclose to other clinicians without proper consent. These other clinicians be-
lieved such information would be invaluable in the clients' treatment plans. The problem
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was further complicated for pregnant addicts, because a particular physician could be both
a researcher and a clinician for them. How could the clinician advise the obstetric and
pediatric staffs at the hospital where the clinician practiced, and where the clients would
deliver their babies, to take precautions against blood exposure from mother and infant
without disclosing the mother's HIV antibody status, learned only through research?
Should all high-risk mothers and infants be considered infectious?
In AIDS research, it may be important to distinguish between confidentiality and ano-
nymity. If the only concern is an epidemiological analysis of prevalence, then anonymity
may be preferred. However, if there are good reasons — such as the ability to trace a
person with AIDS in order to provide therapeutically relevant data or to alert a victim that
a new therapy is available— then keeping patients' names in confidential files may be
preferred. IRBs have emphasized this distinction and have challenged researchers to de-
cide whether anonymity or confidentiality is preferable and for what reasons.
Conclusion
The ethical and societal concerns about AIDS research which are raised by the relation-
ship between research findings, available clinical treatments, and public health policy
actions call for a national assessment of medical research priorities and intermediate goals
for AIDS research. 13 Assessments must then lead to directing research funds in accord-
ance with the national research agenda in the most cost-efficient manner. Such a public
policy could be cooperatively addressed by private researchers and institutions and public
agencies and officials. To some extent, such forums have already been established in
various states. For example, in Massachusetts the Governor's Task Force on AIDS is
composed of researchers, public health officials, and community representatives. All of
the New England states have established similar investigational bodies. State plans should
be consistent with broader, more comprehensive national agendas.
Many ethical, legal, and public policy considerations are involved in addressing the
problems associated with AIDS research. Professionals in all aspects of health care need
to recognize and understand the possible alternative approaches to resolution of these
practical and moral quandaries. IRBs can serve as locally based forums for the initiation
of debate. Such boards have had ample experience in dealing with the substantive issues of
consent, confidentiality, the balancing of risks and benefits, and the proper selection of
populations for research. This experience is complemented by federally mandated guide-
lines that assure proper procedures for the protection of human subjects in research. Since
the procedures are open to public scrutiny and since these boards have public representa-
tion, IRBs are particularly appropriate forums for public participation in addressing
AIDS research.
Although the principles of biomedical ethics, such as beneficence, justice, and respect
for persons, are not unique to AIDS research, the enormity and gravity of AIDS necessi-
tate a careful application of these principles. The continuous balancing of the rights and
welfare of individuals and the rights and welfare of the public is a crucial element in re-
solving the complex ethical issues involved in AIDS research. *§>
This article is an adaptation of a paper entitled "Ethical Issues in AIDS Research," which
originally appeared in October 1986 in the Quality Review Bulletin (volume 12, number
10). The article is printed by permission of the Joint Commission on Accreditation of
Healthcare Organizations.
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"Someone once describedAIDS like being in a canoe in the
middle ofa hurricane. It's pretty lonely and its pretty terrifying.
But when someone is in that canoe with you it's not nearly so
frightening. So it is with our coalition ofPWAs. We even believe
that we can bring that canoe into a safe harbor.
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